Race Oncology
Clinical-stage biopharmaceutical company developing a reformulated small-molecule chemotherapeutic intended to retain anticancer activity while reducing cardiotoxicity and enabling peripheral intravenous administration. Activities include preclinical mechanism-of-action and cardioprotection studies, cGMP manufacture of a clinical formulation, IND-enabling data generation, and multi-site Phase I clinical trials. The company also manages collaborations, IP protection and investor communications.
Industries
Nr. of Employees
small (1-50)
Race Oncology
L36, 1 Macquarie Place, Sydney, NSW 2000, Australia
Patents
Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-11147800-B2
View DetailsCompositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-11135201-B2
View DetailsCompositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-10548876-B2
View DetailsCombinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-10500192-B2
View DetailsCompositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-9993460-B2
View DetailsCombinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-9974774-B2
View Details
Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-11147800-B2
View DetailsCompositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-11135201-B2
View DetailsCompositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-10548876-B2
View DetailsCombinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-10500192-B2
View DetailsCompositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-9993460-B2
View DetailsCombinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US-9974774-B2
View DetailsProducts
Clinical-stage reformulated small-molecule chemotherapeutic formulation for peripheral IV administration
A reformulated clinical candidate derived from a historical anthracene-class chemotherapeutic, developed to allow peripheral intravenous delivery, with the objective of reducing cardiotoxicity and enabling combination use with anthracyclines.
Clinical-stage reformulated small-molecule chemotherapeutic formulation for peripheral IV administration
A reformulated clinical candidate derived from a historical anthracene-class chemotherapeutic, developed to allow peripheral intravenous delivery, with the objective of reducing cardiotoxicity and enabling combination use with anthracyclines.
Services
Design, sponsor and operate early-phase clinical trials to evaluate safety, tolerability and pharmacokinetics of reformulated chemotherapeutic candidates, including multi-site international sites.
Supply of clinical-grade reformulated drug formulation to external researchers for preclinical studies upon request.
Engagement with research institutions and industry partners to negotiate licences, collaborations and potential commercial transactions to accelerate development and access.
Design, sponsor and operate early-phase clinical trials to evaluate safety, tolerability and pharmacokinetics of reformulated chemotherapeutic candidates, including multi-site international sites.
Supply of clinical-grade reformulated drug formulation to external researchers for preclinical studies upon request.
Engagement with research institutions and industry partners to negotiate licences, collaborations and potential commercial transactions to accelerate development and access.
Expertise Areas
- Oncology drug development
- Intravenous formulation development
- Cardio-oncology and cardioprotection research
- Early-phase clinical trial management
Key Technologies
- Small-molecule chemotherapeutic development
- Intravenous formulation engineering
- In vitro cancer cell assays
- Human primary cardiomyocyte assays
News & Updates
Phase 1 study investigating safety and pharmacokinetics of a reformulated chemotherapeutic in combination with doxorubicin in patients with advanced solid tumours; trial sites include Australia, Hong Kong and South Korea. (ClinicalTrials.gov NCT06815575)
Company Annual General Meeting held 24 November 2025 in Sydney, NSW.
Collection of investor presentations, briefing slides and conference presentations for investor review.
Quarterly activity reports, Appendix 4C filings and annual reports available from the investor centre.
Webinars and recorded presentations covering mechanism-of-action research, trial updates and investor briefings on the company YouTube channel.
Media articles and interviews covering the company’s discovery work on mechanism of action, IP advancements and clinical trial site activations.
Phase 1 study investigating safety and pharmacokinetics of a reformulated chemotherapeutic in combination with doxorubicin in patients with advanced solid tumours; trial sites include Australia, Hong Kong and South Korea. (ClinicalTrials.gov NCT06815575)
Company Annual General Meeting held 24 November 2025 in Sydney, NSW.
Collection of investor presentations, briefing slides and conference presentations for investor review.
Quarterly activity reports, Appendix 4C filings and annual reports available from the investor centre.
Webinars and recorded presentations covering mechanism-of-action research, trial updates and investor briefings on the company YouTube channel.
Media articles and interviews covering the company’s discovery work on mechanism of action, IP advancements and clinical trial site activations.